Improving Early Lung Cancer Detection in a Diverse Population (IDEAL)

A Project of the Real World Evidence Program

  • Principal Investigators: Renelle Myers, Vancouver General Hospital, University of British Columbia, BC Cancer; Rayjean Hung, Mount Sinai Hospital, University of Toronto
  • Co-Investigators: Stuart Peacock, Stephen Lam, G Liu, S Martel, M Tammemagi, R Meza, C MacAulay, K Campbell, M McInnis, R Rajapakshe, J Leipsic, D Ruszkiewics, J Jeon, M Johansson, H Robbins, J Yee, T Shaipanicj, K Yasufuku, J Mayo, MH Denault, M Bradley, W Callahan, A Callahan, C Di Poala
  • Funding Source: Canadian Cancer Society
  • Project Launch: July 2023

Improving Early Lung Cancer Detection in a Diverse Population (IDEAL) study is a research program focused on incidental pulmonary nodules and lung cancer early detection. It is a multi-province program in British Columbia, Ontario and Quebec, with the goal to develop innovative tools to improve lung cancer early detection through non- or minimally invasive approaches, such as breath and blood tests.

As part of knowledge translation and implementation, the CanSurvive Research Group is evaluating the cost-effectiveness of these novel approaches based on resource utilization in the Canadian healthcare system, and their impact on individuals’ quality of life.

View Other Projects in the Real World Evidence Program

The CDA Post Marketing Drug Evaluation Program and the Canadian Cancer Real-world Evaluation (CCRE) Platform

Co-Principal Investigators: Stuart Peacock, BC Cancer, Simon Fraser University; Kelvin Chan, Sunnybrook Odette Cancer Centre, University of Toronto; Winson Cheung, University of Calgary; Scott Gavura, Ontario Health; J Irish; M Tadrous

Improving Early Lung Cancer Detection in a Diverse Population (IDEAL)

Principal Investigators: Dr. Renelle Myers, Vancouver General Hospital, University of British Columbia, BC Cancer; Dr. Rayjean Hung, Mount Sinai Hospital, University of Toronto

Cost-effectiveness Analysis of Gene Profiling Using Tumour Tissue in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Principal Investigator: Steven Gallinger, Princess Margaret Cancer Centre, University of Toronto

View More

National Program on Radioligand Therapy for Prostate Cancer

Co-Principal Investigators: Stuart Peacock, BC Cancer, Simon Fraser University; Francois Bernard, BC Cancer, University of British Columbia; J Valliant; F Prato, W Isaranu-watchai, F Wuest, J Beauregard, K Zukotynski, K Chi, F Saad

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.